218 related articles for article (PubMed ID: 22030597)
41. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Calhoun DA; Crikelair NA; Yen J; Glazer RD
Adv Ther; 2009 Nov; 26(11):1012-23. PubMed ID: 20024680
[TBL] [Abstract][Full Text] [Related]
42. Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Ram CV
Expert Rev Cardiovasc Ther; 2011 Jan; 9(1):9-19. PubMed ID: 21166525
[TBL] [Abstract][Full Text] [Related]
43. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study.
Kreutz R; Scholze J; Douros A
Curr Vasc Pharmacol; 2018 Jan; 16(2):197-203. PubMed ID: 28828980
[TBL] [Abstract][Full Text] [Related]
44. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis.
Agarwal R; Weir MR
J Hypertens; 2013 Aug; 31(8):1692-701. PubMed ID: 23697963
[TBL] [Abstract][Full Text] [Related]
45. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Chrysant SG
Clin Drug Investig; 2010; 30(7):473-82. PubMed ID: 20528002
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Nesbitt SD; Shojaee A; Maa JF; Weir MR
J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.
Parati G; Ochoa JE; Ramos C; Hoshide S; Lonati L; Bilo G
Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):301-13. PubMed ID: 20921092
[TBL] [Abstract][Full Text] [Related]
48. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
Weir MR; Ferdinand KC; Flack JM; Jamerson KA; Daley W; Zelenkofske S
Hypertension; 2005 Sep; 46(3):508-13. PubMed ID: 16116046
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Hsueh WA; Shojaee A; Maa JF; Neutel JM
Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496
[TBL] [Abstract][Full Text] [Related]
50. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Chrysant SG
Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
[TBL] [Abstract][Full Text] [Related]
51. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Tocci G; Paneni F; Passerini J; Volpe M
Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.
Chrysant SG; Oparil S; Melino M; Karki S; Lee J; Heyrman R
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):475-82. PubMed ID: 19751459
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Punzi HA
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):229-39. PubMed ID: 19296759
[TBL] [Abstract][Full Text] [Related]
55. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study).
Jung HW; Kim KI; Park CG; Kang DH; Ahn Y; Bae JH; Kim CH
Clin Exp Hypertens; 2015; 37(6):482-9. PubMed ID: 25816197
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.
Bramlage P; Wolf WP; Stuhr T; Fronk EM; Erdlenbruch W; Ketelhut R; Schmieder RE
Vasc Health Risk Manag; 2010 Sep; 6():803-11. PubMed ID: 20859549
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Israel M; Lee J; Purkayastha D; Jaimes EA
J Am Soc Hypertens; 2011; 5(2):102-13. PubMed ID: 21414565
[TBL] [Abstract][Full Text] [Related]
58. Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.
Ofili EO; Oparil S; Giles T; Pitt B; Purkayastha D; Hilkert R; Samuel R; Sowers JR
J Am Soc Hypertens; 2011; 5(4):249-58. PubMed ID: 21482217
[TBL] [Abstract][Full Text] [Related]
59. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
Heagerty AM; Mallion JM
Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study.
Sung KC; Oh YS; Cha DH; Hong SJ; Won KH; Yoo KD; Rha SW; Ahn YK; Ahn JC; Jang JY; Hong TJ; Cho SK; Park SH; Hyon MS; Nam CW; Chae IH; Yoo BS; Song JM; Jeong JO; Yoon YW; Kim BS; Yang TH; Cho DK; Kim SH; Choi YJ; Ahn JH; Jeon DW; Kim HS
Clin Ther; 2018 Jan; 40(1):50-63.e3. PubMed ID: 29248384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
